AI in Healthcare

The latest on artificial intelligence transforming medicine

News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.

Filtered by: platform strategyClear filter
industryGlobeNewswire

Nexalin’s Digital Health Acquisition Shows Neurostimulation Is Going AI-Native

Nexalin’s acquisition of a digital health platform suggests the company is trying to pair neurostimulation with AI-driven software capabilities. The deal reflects a larger trend: device companies are increasingly buying digital infrastructure to deepen product differentiation and data access.

neurostimulationdigital health acquisitionAI integrationmedtech
industry

IKS Health Buys ARAI to Deepen Its Specialized AI Stack

IKS Health acquired ARAI in a move aimed at expanding its specialized AI capabilities. The deal reflects a broader industry trend: vendors are no longer just adding AI features, but assembling deeper, domain-specific toolchains to compete on workflow integration.

MedCity News
healthcare aiacquisitionworkflow automation
industry

Doximity’s AI Ambition Is Bigger Than Features — It Is About Network Effects

A new analysis of Doximity asks whether the company can turn physician-network scale into a durable AI advantage. The core question is whether distribution, data, and workflow proximity can create a moat stronger than model quality alone.

simplywall.st
Doximityplatform strategyphysician network
industry

Mobile-health Network Solutions Bets $119 Million on AI-Driven Expansion Across Asia and Africa

Mobile-health Network Solutions says it has entered a non-binding US$119 million strategic framework with Hector Capital to acquire BIMA and M&M Helix, aiming to accelerate AI-powered healthcare expansion across Asia and Africa. The deal underscores how digital health companies are using M&A and platform consolidation to chase scale in emerging markets.

TradingView
digital healthM&AAsia
industry

Big Tech’s Drug Discovery Push Is Turning AI Into a Life Sciences Platform War

Axios reports that Big Tech is circling drug discovery, reinforcing the idea that life sciences is becoming a strategic battleground for AI platforms. As major technology companies move closer to pharma, the competition is shifting from standalone tools to end-to-end ecosystems that can own the scientific workflow.

Axios
Big Techdrug discoverylife sciences AI
industry

Microsoft’s Healthcare AI Push Highlights the Difference Between Promise and Proof

Microsoft is showcasing seven ways AI is advancing health and wellbeing around the world, part of a broader effort to frame AI as infrastructure for healthcare transformation. The key question is whether these benefits are broadly scalable or still mostly pilot-stage narratives.

Microsoft Source
big techhealth AIglobal health
industry

Amazon Pushes Into AI Drug Discovery With a New Research Tool for Life Sciences

Amazon’s launch of an AI research tool for early drug discovery shows how cloud giants are trying to own more of the scientific workflow, not just the compute layer. The move could make advanced discovery tools more accessible, while also intensifying competition for pharmaceutical data and platform control.

Reuters
AmazonAWSAI drug discovery
industry

Insilico’s Pharma.AI Event Highlights the Industry’s Shift From AI Pilots to Platform Strategy

Insilico Medicine’s Pharma.AI Spring Kickoff reflects a wider transformation in drug discovery: AI is increasingly being treated as a platform rather than a point solution. The event underscores how companies are trying to move from isolated applications to integrated intelligence across the entire R&D workflow.

Insilico Medicine
Insilico Medicinepharma AIplatform strategy
technology

The Spread of AI Discovery Deals Shows Biopharma Is Building an Ecosystem, Not Backing One Model

A cluster of recent partnership announcements suggests biopharma is constructing a layered AI discovery ecosystem rather than choosing a single dominant platform. That diversification reflects both scientific uncertainty and a growing belief that different AI tools will matter at different stages of R&D.

BioPharma APAC
AI ecosystemdrug discoverybiopharma partnerships
technology

Shuttle Pharma Expands Its AI Discovery Platform, Underscoring AI’s Shift From Feature to Operating Layer

Shuttle Pharma’s platform expansion, as reported by Investing.com, reflects a broader market trend: AI is being positioned as an ongoing capability layer across discovery programs rather than a one-off tool. The move suggests more biopharma companies are trying to institutionalize AI inside their development operations.

Investing.com
Shuttle PharmaAI platformdrug discovery
industry

DocMorris and Google AI Bet on a European Platform Model for Digital Health

DocMorris’s move to use Google AI for a next-generation European digital health platform highlights how AI is becoming foundational to cross-service healthcare commerce. The significance lies less in the branding of the partnership than in the platform logic: integrating pharmacy, navigation, and personalization at regional scale.

TipRanks
DocMorrisGoogle AIEurope
industry

CVS and Google Cloud Push Consumer Health AI Into the Platform Era

CVS Health’s partnership with Google Cloud to build an AI-driven consumer health platform highlights where major healthcare incumbents see the next battleground: patient-facing orchestration at scale. The move suggests AI’s strategic value is shifting from isolated tools to integrated retail-clinical engagement systems.

ERP Today
CVS HealthGoogle Cloudconsumer health
opinion

Small Meets Large: Pharma Rethinks the Molecule Divide in a More AI-Native R&D Model

A new industry analysis argues that the historic split between small molecules and large molecules is becoming less useful in pharmaceutical R&D. As AI-driven design and platform biology mature, developers are increasingly organizing around disease mechanisms, developability, and modality fit rather than legacy chemistry silos.

drugdiscoverytrends.com
pharma R&Dsmall moleculesbiologics
industry

Two AI Drug-Design Startups Show the Field Is Competing on Toolchains, Not Just Models

A FirstWord Pharma look at two AI startups’ internal tooling highlights a maturing competitive landscape in which platform differentiation increasingly comes from integrated toolchains rather than single breakthrough models. For pharma buyers and investors, that is a useful signal that discovery AI is becoming an engineering discipline as much as a scientific one.

FirstWord Pharma
AI startupsdrug designtoolchains

How this works

Discover

An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.

Structure

The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.

Publish

Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.